[by Yu, Suin] Dong-A ST is accelerating the market entry of its Stelara biosimilar, 'Imuldosa (ustekinumab),' into key European countries.According to industry sources on April 7, Imuldosa was additionally launched in the United Kingdom and Ireland, following its initial release in Germany this Janu
[by Ji, Yong Jun] Daewoong Pharmaceutical has announced the launch of 'Fexuclue' in India, marking the company’s full-scale entry into the world's fourth-largest antiulcer drug market. This launch represents the first instance of a domestically developed potassium-competitive acid blocker (P-CAB) dr
[by Yu, Suin] ENCell disclosed on April 7 its phased global expansion strategy for 'EN001’ (development code), a treatment candidate currently under development.The company is actively pursuing out-licensing (L/O) opportunities, leveraging the momentum gained from the U.S. Food and Drug Administrati
[by Yu, Suin] AstraZeneca Korea announced on April 7 that its immunotherapy drug 'Imfinzi (durvalumab)' has received approval from the Ministry of Food and Drug Safety for the treatment of 'limited-stage small cell lung cancer (LS-SCLC).'With this approval, Imfinzi is now authorized for use as a mon
[by Yu, Suin] “Certain pipeline candidates have completed due diligence processes for technology transfer with major pharmaceutical companies and are now entering discussions regarding the signing of a term sheet. The first outcomes of these technology transfer agreements are anticipated to be annou
[by Ji, Yong Jun] “The combination therapy of ‘lazertinib (marketed in Korea as Leclaza and internationally as Lazcluze) + amivantamab (commercial name Rybrevant) is projected to yield a median overall survival (mOS) of approximately 55 months in patients. Given the current trajectory of clinical ou
[더바이오 지용준 기자] “‘레이저티닙(국내 제품명 렉라자/ 미국·유럽 제품명 라즈클루즈)+아미반타맙(제품명 리브리반트) 병용요법’은 환자의 전체 생존기간 중앙값(mOS)의 55개월 달성을 기대해 볼 만합니다. 현재 추세라면 연내 ‘미국 종합암네트워크(NCCN) 선호요법 등재’도 유력할 것으로 보입니다.”‘라즈클루즈+리브리반트' 병용요법 개발의 주역 중 한 명인 조병철 연세암병원 폐암센터장(세브란스병원 종양내과 교수)은 지난 1일 서울 서대문구 연세대 에비슨의생명연구센터에서 와 인터뷰를 갖고 이같이 말했다. 조병철 교수는
[by Kang, In Hyo] Celltrion announced on April 3 its decision to acquire an additional KRW 100 billion (approximately USD 69.2 million) worth of treasury stocks today. This move follows the company’s resolution on the previous day (April 2) to retire a portion of its existing treasury shares.This ma
[by Yu, Suin] Coreline Soft, an AI-driven medical imaging solutions company, announced its participation in the 'AGILE DxRx 2025' conference, scheduled to take place in Bangkok, Thailand, from April 3 to 5. During the event, the company intends to present the advancements and future vision of its AI
[by Yu, Suin] L&K Biomed announced on April 3 that it has successfully completed Transforaminal Lumbar Interbody Fusion (TLIF) surgery using its height-expandable cage, ‘AccelFix-XT,’ at both Clementine Churchill Hospital in the United Kingdom and Cho Ray Hospital in Vietnam.In early March, L&K Biom
[by Sung, Jae Jun] Huonslab, a subsidiary of Huons Global, announced on April 3 that its abstract titled “The Role of HyDIFFUZE™ in Co-formulation with Subcutaneous Infliximab” has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, t
[by Kang, In Hyo] MEDI.SOLA, a company specializing in customized food care solutions, announced on April 3 that it has successfully secured KRW 13 billion (approximately USD 8.8 million) in Series A funding. Key investors in this round included Premier Partners, Samsung Venture Investment, and Redb
[by Kang, In Hyo] SillaJen announced on April 3 that five prominent cancer research institutions in the U.S., including MD Anderson Cancer Center, Yale Cancer Center, and Montefiore Einstein Comprehensive Cancer Center, along with one institution in Korea, will participate in the clinical trial of ‘
[by Sung, Jae Jun] The Korea Biotechnology Industry Organization (KoreaBIO) announced on April 3 that it will host the '2025 BIO Regulatory Innovation Conference' to support Korean biotechnology companies' in entering the U.S. market.The conference is scheduled to take place on April 23 and 24 at th
[by Yu, Suin] Gencurix announced on April 1 the release of clinical results for 'HEPA eDX,' an early diagnosis test for liver cancer, along with preliminary findings from a study investigating its effectiveness in monitoring recurrence after treatment.According to the company, the study findings wer
[by Yu, Suin] Huons Group's biologics-specialized affiliated company PanGen Biotech announced on April 2nd that it has signed a contract manufacturing organization (CMO) agreement with CHA Biotech Group's CHA Vaccine Institute.CHA Vaccine Institute is a KOSDAQ-listed company that develops next-gener
[by Ji, Yong Jun] D&D Pharmatech announced on April 2 its decision to register an Australian patent for its metabolic dysfunction-associated steatohepatitis (MASH) treatment candidate, 'DD01 (development code)', currently under development. The company noted that this marks the first overseas patent
[by Ji, Yong Jun] Abion disclosed on April 1 that it entered into a term sheet agreement (MOU) outlining the terms for the technology transfer of ‘vabametkib,’ an anticancer drug candidate (development code: ‘ABN401’), to a multinational pharmaceutical company headquartered in Russia and four member
[by Ji, Yong Jun] AbClon announced on March 31 that it will present the latest research findings on its immunotherapy candidate, 'AM105’ (development code), at the annual meeting of the American Association for Cancer Research (AACR).The AACR annual meeting, scheduled to take place in Chicago, USA,
[by Ji, Yong Jun] ENCell, a contract development and manufacturing organization (CDMO) specializing in advanced biopharmaceuticals and new drug development, announced on April 1 that it has completed a patent application with the Korean Intellectual Property Office for its ‘Adeno-Associated Virus (A
